Abacavir versus Zidovudine-Based Regimens for treatment of HIV-Infected Children in resource limited settings: A Retrospective Cohort Study

Abstract

BackgroundAbacavir (ABC) and Zidovudine(AZT) based regimens are the preferred first line nucleoside reverse transcriptase (NRTIs) backbones being widely utilized for managing HIV infection in children. However, there is a dearth of data regarding the clinical outcomes and associated risk factors in Ethiopia. We compared the proportion of mortality and the rate of occurrence of Opportunistic Infections (OIs) with ABC versus AZT based regimens in a cohort of HIV-infected children. MethodsA 42 months retrospective cohort study was conducted. A total of 179 records were reviewed by including data from October 2014 to April 2017. Data were collected on socio-demographic, clinical characteristics of patients and drug related variables. Data were analyzed using STATA13.1. Kaplan-Meier and Cox regression were used to compare survival experience and identify independent predictors. Propensity score matching analysis was conducted to elucidate the average treatment effects of each regimen over OIs.ResultOf 179 patients, 98 (54.7%) were females. The mean (+SD) age of the study subjects was 6.53 ± 2.83 years. Through 42 months analysis, a total of 4 patients (1 (1.14%) from ABC group and 3 (3.3%) from AZT group (p=0.339)) were died. The incidence of opportunistic infections attributed to ABC group was 8.77/100,000 person years (py) and that of AZT was 6.9/100,000py. The incidence rate ratio (IRR) for OIs was (IRR=0.87, 95% CI [0.49-1.53] (p=0.304). Baseline CD4 count (AHR= 0.99, 95% CI [0.98-0.99]), Severe acute malnutrition AHR=15.92, 95% CI [5.34-47.50], and exposure to tuberculosis treatment (AHR=2.93, 95% CI [1.39-6.17]) were the independent predictors for the development of OIs. ConclusionABC and AZT based ART regimens seem to have comparable survival benefit among HIV-infected children in Ethiopia. Therefore, both regimens might be used as an alternative in resource limited settings.

Broad spectrum antiviral nucleosides—Our best hope for the future

“…11), are carbocyclic nucleosides used to treat HIV. 24,[74][75][76] Notably, abacavir is one of the few drugs available for use in children with HIV. 76…”

“…24,[74][75][76] Notably, abacavir is one of the few drugs available for use in children with HIV. 76…”